Visit number | V1 Screening | V2 baseline/start of treatment | V3 | V4 | V5 | V6 final visit/end of study |
Time (days) | −7/−3 | 0 | 7±2 | 14±2 | 28±2 | 42±3 |
Written informed consent | X | |||||
Demographic data | X | |||||
Vital signs (1) | X | X | X | X | X | X |
Measurement of body temperature | X | X | X | X | X | X |
Physical examination | X | |||||
Medical history and concomitant diseases | X | |||||
Prior and concomitant medication (2) | X | X | X | X | X | X |
Urine pregnancy test (3) | X | |||||
Identification and evaluation of the target lesion | X(4) | |||||
Photo of the target lesion | X | X | X | X | X | |
Measurement of the area of the target lesion | X | X | X | X | X | |
Evaluation of the clinical signs of infection | X | X | X | X | X | X |
Cleaning or medication of lesion(s) | X | X | X | X | X | X |
Swab collection of the infected target lesion | X(5) | X | X | |||
Study eligibility (inclusion and exclusion criteria) | X | X | ||||
Randomisation | X | |||||
Schedule of oxygen-ozone therapy (6) | X | X | X | X | ||
Prescription of oral antibiotic therapy (7) | X | X | ||||
Bacteriological response | X | X | ||||
Investigator’s global assessment | X | X | ||||
Laboratory parameters | X | X | X | |||
Assessment of compliance to antibiotics | X | X | X | X | ||
Adverse events | X | X | X | X | X | X |